Hepatitis B study (S18ENY08)

This is a clinical study of a new treatment people with chronic (long term) hepatitis B. The new treatment is a medicine called EYP001a. EYP001a is a tablet that is taken daily for 4 weeks.

EYP001a has previously been administered in humans in single and multiple doses and was found to be safe and well tolerated.

This research study will be conducted in 2 parts. Whether you are enrolled in the first part (Part A) or the second part (Part B) of the study will depend on when you join the study.

Part A
If you participate in Part A, you will receive EYP001a to see what effects it may have on you and your chronic hepatitis B.

The main purpose of this study is to determine if EYP001a can be administered for 4 weeks at different doses safely and without unacceptable side effects. EYP001a on its own will be compared with the administration of an approved treatment for chronic hepatitis B called entecavir.

Part B
If you participate in Part B, you may receive EYP001a in combination with one of the currently approved chronic hepatitis B medicines to see what effects it may have on you and your chronic hepatitis B.

The main purpose of this study is to determine if EYP001a can be administered for 4 weeks at different doses in combination with a standard of care hepatitis B treatment safely and without unacceptable side effects. The approved treatment to be used in this study is Pegylated interon alpha 2a also known as Pegasys.

This clinical study is currently recruiting participants.

If you would like more information, register below or call 1800 727 874.

Not required

Weekly visits for 6 to 8 weeks

* have chronic hepatitis B (HBV infection).
* have a suitable height and weight
* have suitable blood test results

When enquiring about this clinical study please quote the study code above